Point72 Asset Management’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
Other funds holding DNTH
FFM
APM
OCA
Point72 Asset Management's DNTH Position: Q2 2026 in Review
Point72 Asset Management sold out of Dianthus Therapeutics (DNTH) in Q2 2026, closing a stake of 643,599 shares — an estimated $54M sold.
Point72 Asset Management first reported a position in DNTH in Q2 2018 and held it in 10 quarters. The position peaked at $80.4M in Q3 2025. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.
- Point72 Asset Management reported no remaining Dianthus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Point72 Asset Management sold 643,599 Dianthus Therapeutics shares in Q2 2026, an estimated $54M.
- Point72 Asset Management first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 10 quarters.
- Point72 Asset Management's Dianthus Therapeutics position peaked at $80.4M in Q3 2025.
- 268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.
Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.